Trials / Unknown
UnknownNCT04534998
Robotic-assisted vs. Open Partial Nephrectomy
ROBOtic-assisted Versus Conventional Open Partial Nephrectomy: a Single-center, Open-label, Randomized Controlled Feasibility Trial
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Universitätsmedizin Mannheim · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
ROBOCOP is an open-label, randomized controlled feasibility trial comparing robotic-assisted and open partial nephrectomy in preparation for a confirmative phase III randomized controlled trial.
Detailed description
Surgical excision is the gold standard for the treatment for localized kidney cancer. An organ-preserving procedure should be carried out whenever possible in order to maintain kidney function. Partial nephrectomy can be performed through the conventional open technique as well as through a robotic-assisted approach. Although both methods belong to the standard care, there is still no published data from randomized controlled trials in the scientific literature comparing them. The ROBOCOP-trial is designed as a single-center comparison of the two surgical approaches in preparation for a phase III study. 50 patients are to be included in the trial within a period of 15 months. The primary endpoint is feasibility of patient recruitment. In addition, potential primary outcomes for a confirmative trial such as perioperative complications, quality of life, inflammatory response, survival and ergonomic aspects for the operating surgeons will be investigated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Partial nephrectomy | Partial nephrectomy for localized kidney cancer as curative treatment. |
Timeline
- Start date
- 2020-06-15
- Primary completion
- 2021-12-15
- Completion
- 2022-03-15
- First posted
- 2020-09-01
- Last updated
- 2021-09-13
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT04534998. Inclusion in this directory is not an endorsement.